were losing 3% after the biotech company said that a low dose of its cancer drug Avastin worked just as well as a more-expensive high dose during clinical trials. The news stirred up fears that the company will receive less revenue from sales of the drug, and Genentech was falling $2.61 to $85.13.
was trading lower despite the final approval from the Food and Drug Administration for rabeprazole sodium delayed-release tablets, a generic form of Aciphex. Teva shares were losing 69 cents, or 1.8%, to $37.65.
On the winning side,
posted a narrower-than-expected fourth-quarter loss late Wednesday. The company also beat the Thomson First Call quarterly revenue estimate. OSI was recently adding 91 cents, or 2.6%, to $36.26.
was gaining 2% even after the company missed fourth-quarter earnings targets when it reported following the previous session's close. However, PDL said it expects 2007 revenue to rise due to product sales and royalty payments. The stock was adding 38 cents to $19.52.
Among other winners,
was rising 2.6% to $1.99.
was gaining 1.6% to $53.57.
As for decliners,
was sliding by 3.9% to $22.20.
was recently down 1.7% to $28.19.
was off 1.1% to $67.05.